“Intravenous Tocilizumab versus Standard of Care in the Treatment of Severe and Critical COVID-19-related Pneumonia: A Single Center, Double-blind, Placebo Controlled, Phase 3 Trial ” (2024) Acta Medica Philippina, 58(6). doi:10.47895/amp.vi0.6175.